Corneal Changes in Trastuzumab Emtansine Treatment

Clin Breast Cancer. 2018 Aug;18(4):e427-e429. doi: 10.1016/j.clbc.2018.03.005. Epub 2018 Mar 12.

Authors

Elke O Kreps¹, Thierry Derveaux², Hannelore Denys³

Affiliations

¹ Department of Ophthalmology, Ghent University Hospitals, Ghent, Belgium. Electronic address: elke.kreps@ugent.be.
² Department of Ophthalmology, Ghent University Hospitals, Ghent, Belgium.
³ Department of Medical Oncology, Ghent University Hospitals, Ghent, Belgium.

PMID: 29615304
DOI: 10.1016/j.clbc.2018.03.005

No abstract available

Keywords: Antibody–drug conjugates; Autologous serum; Corneal toxicity; HER2; Microcystic epitheliopathy.

Publication types

Case Reports

MeSH terms

Ado-Trastuzumab Emtansine
Adult
Antineoplastic Agents, Immunological* / adverse effects
Antineoplastic Agents, Immunological* / pharmacology
Antineoplastic Agents, Immunological* / therapeutic use
Breast Neoplasms / drug therapy*
Carcinoma, Ductal, Breast / drug therapy*
Epithelium, Corneal / drug effects*
Epithelium, Corneal / pathology
Female
Humans
Maytansine / adverse effects
Maytansine / analogs & derivatives
Maytansine / pharmacology
Maytansine / therapeutic use
Ophthalmic Solutions / administration & dosage
Receptor, ErbB-2 / antagonists & inhibitors
Receptor, ErbB-2 / metabolism
Trastuzumab / adverse effects
Trastuzumab / pharmacology
Trastuzumab / therapeutic use
Treatment Outcome
Vision Disorders / chemically induced*
Vision Disorders / pathology
Vision Disorders / therapy

Substances

Antineoplastic Agents, Immunological
Ophthalmic Solutions
Maytansine
ERBB2 protein, human
Receptor, ErbB-2
Trastuzumab
Ado-Trastuzumab Emtansine